Successful Lipid Lowering With Alirocumab and Bempedoic Acid in a Statin-Intolerant Heterozygous Familial Hypercholesterolemia With Markedly Elevated Lipoprotein(a): A Case Report
Intensive lipid lowering is essential in the management of heterozygous familial hypercholesterolaemia (HeFH). Statin intolerance necessitates consideration of alternative lipid-lowering therapies, while concomitantly elevated lipoprotein(a) (Lp(a)) further increases cardiovascular risk and the importance of adequate lipid reduction. We report the case of a 66-year-old woman with severe statin intolerance and dyslipidaemia. Following assessment in the lipid clinic, she was identified to have genetically confirmed HeFH with severely elevated Lp(a) at 617 nmol/L. Her computerized tomography coronary angiogram (CTCA) demonstrated unobstructed coronary arteries with no lesions seen, and her coronary artery calcium (CAC) score was 0. Despite a baseline low-density lipoprotein cholesterol (LDL-C) of 8.4 mmol/L and non-high-density lipoprotein cholesterol (non-HDL-C) of 9.1 mmol/L in July 2025, her lipid parameters improved substantially with alirocumab and bempedoic acid. LDL-C improved by 69.0% to 2.6 mmol/L, and non-HDL-C decreased by 64.8% from baseline to a level of 3.2 mmol/L. As non-HDL-C remained above the target of <2.5 mmol/L, ezetimibe was subsequently added.
Authors
- Preet Mukesh Shah
- Madhura S Nootigattu
Institutions
- London North West Healthcare NHS Trust (GB)
Publication Details
- Journal
- Cureus
- Published
- 2026-11-18
- DOI
- https://doi.org/10.7759/cureus.119906
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00